Oxcia reports an operating result of -9.3 MSEK for the third quarter
The period's result amounted to -9.3 MSEK and cash flow from ongoing operations was -7.6 MSEK. OXC-201 received orphan drug status from both EMA and FDA for idiopathic pulmonary fibrosis.